2022 World Conference on Lung Cancer (ePosters)-EP14.05-023. Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States

EP14.05-023. Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States

Back to course

Pdf Summary

Lurbinectedin is a novel drug that has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC). It is the first treatment option for relapsed/refractory SCLC approved in over 20 years. This study aimed to characterize the real-world use of lurbinectedin in adult patients with SCLC in the United States.<br /><br />The study used the Flatiron Health electronic health record-derived database, which includes de-identified patient-level data. Adult patients who were treated with lurbinectedin between June 2020 and March 2022 were included in the study. Patients who participated in a clinical trial or had no medical visits within 90 days after their initial SCLC diagnosis were excluded.<br /><br />The study found that the majority of patients received lurbinectedin as second-line therapy at the recommended dose. Among patients who had received chemotherapy prior to lurbinectedin, a wide range of chemotherapy-free intervals was observed, with some patients having a gap of 180 days.<br /><br />The median age of patients treated with lurbinectedin was 67 years, and most patients had extensive-stage disease at initial diagnosis. The study also found that concomitant growth factor use was seen in 45% of patients. The most common treatments in the line prior to lurbinectedin were platinum etoposide with or without immunotherapy, while topotecan was the most common treatment after lurbinectedin.<br /><br />In conclusion, the real-world use of lurbinectedin in adult patients with SCLC reflects its approved use as per the label. The majority of patients received lurbinectedin as second-line therapy, and the treatment was generally well-tolerated. The study provides insights into the characteristics, clinical profile, and treatment patterns of patients treated with lurbinectedin in the United States.

Asset Subtitle

Xue Wang

Meta Tag

Speaker Xue Wang

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

Keywords

Lurbinectedin

novel drug

US Food and Drug Administration

metastatic small cell lung cancer

relapsed/refractory SCLC

real-world use

Flatiron Health

electronic health record-derived database

chemotherapy-free intervals

concomitant growth factor use